The written testimony of David A. Prentice, Ph. D., the Vice President and Research Director of the Charlotte Lozier Institute before the Indiana Senate Committee on Health and Provider Services in support of SB 334. This bill would prohibit abortion based on sex or disability.
The California based City of Hope, one of the country’s leading cancer research hospitals, recently sent out birthday greetings to the California Institute for Regenerative Medicine (CIRM), the nation’s leading funder — apart from the federal government – of stem cell research.
“On its 10th birthday, the California Institute for Regenerative Medicine celebrated 10 stem cell therapies that have been approved for clinical trials, including an HIV/AIDS trial at City of Hope,” the message read.
The birthday greeting contained an unintended irony, for while CIRM was approved by California voters a decade ago to give priority funding to human embryonic stem cell research, eight of the 10 approved clinical trials referenced by City of Hope were for research projects using adult and other non-embryonic stem cells.
Diabetes has long been one of the main diseases for which human embryonic stem cell (embryo-destroying) research, or hESCR, was claimed to hold the greatest promise of curing.
But for well over a decade now, ethically contentious human embryonic stem cell research (hESCR) has notably failed to live up to all its hype, with promises of miracle cures within “five to 10 years” remaining unfulfilled.
That remains true today, despite all the renewed hype that accompanied recent reports that researchers had coaxed hESCs into becoming insulin-producing cells.
Researchers using ethically uncontroversial induced pluripotent stem cells (iPSCs) have achieved what appears to be a major breakthrough in understanding the origin and development of Down syndrome, according to a new study recently published in Nature Communications.
In this paper, Dr. Maureen Condic examines scientific evidence for the point at which it is evident that human life begins.
This paper looks at the highly complex genetic condition that is Down syndrome and society’s response to individuals with this condition. This important paper points out that while research to improve the lives of those with Down syndrome has progressed, federal funding for it lags considerably behind that for other genetic disorders. Policy recommendations are made for the support of those with this condition and their families.
This primer on cloning examines the nature and purpose of human cloning in light of recent developments in stem cell technology. The paper points out that all cloning is reproductive and reflects on the immediate outcome of human cloning – a human embryo – while examining the terminology used by cloning advocates to obscure the facts.
This report looks at the continuing pattern of stem cells research funding and finds that grants continue to be given to projects that show the most promise – namely ethical stem cell research.
This paper continues the investigation of stem cell research funding in the United States by examining the funding patterns at the Maryland Stem Cell Research Commission. This investigation reveals that the Maryland Commission is keeping with the trend of investing more money in ethical stem cell research as opposed to embryonic as it is this route which is providing demonstrable results.
A study published last week has shown that ethical adult stem cells can be used to create three-dimensional living tissues that imitate the developing human brain. In their findings, published in the science journal Nature, researchers asserted that, by using human stem cells derived from skin cells, they were able to assemble brain-like pieces of […]
A European grassroots initiative with the bold objective of protecting human life even in its most vulnerable embryonic state has gained considerable support across the continent- collecting over 850,000 signatures from a wide array of nations. The “One of Us” initiative is a valiant effort that has been taken up by groups and individuals across […]
The most recent round of grants by the California Institute for Regenerative Medicine (CIRM) demonstrates – again – where the future of stem cell research lies. As documented in a previous publication on this website, since its first round of grants to specific research projects in 2007, CIRM has been steadily moving away from its […]
Testimony of David A. Prentice, Ph.D., February 7-8, 2013 The following is the written testimony of Dr. Prentice before a Joint Meeting of the Committee on Public Health and Welfare, Kansas Senate and the Committee on Health and Human Services, Kansas House.
A major New England biotech company recently announced that it would begin the process that it hopes will result in the first clinical trial using induced pluripotent stem cells (iPSCs). This is hardly surprising, as the discovery, by Shinya Yamanaka, of the process to produce embryonic-like, fully pluripotent stem cells from ordinary somatic (body) cells has […]
This paper examines the funding pattern of the California Institute for Regenerative Medicine, an institution which characterizes itself as the “largest source of funding for stem cell research outside the NIH.” Tarne demonstrates that funding has moved from grants directed primarily towards embryonic stem cell research toward primarily ethical stem cells research – which has been the only stem cell research to date to result in positive treatments for illnesses.
A recent study from researchers at the University of Washington announced a major step forward in the treatment of genetic diseases and specifically in treating Down syndrome patients. Down syndrome occurs when there is an extra copy of chromosome 21 (hence its alternative name, Trisomy 21) in the individual’s genetic makeup, causing the physical and mental […]
The Nobel Prize for Medicine awarded to Japan’s Shinya Yamanaka last month is a thoroughly deserved recognition of his groundbreaking work in regenerative medicine, work that just five years ago forever changed the way stem cell research is conducted around the globe. It is also welcome recognition for a man who took seriously the ethical […]
Two recent developments involving the California Institute for Regenerative Medicine (CIRM) again serve to underscore the reality that adult and other non-embryonic avenues of stem cell research are advancing at a far more dramatic pace toward providing actual therapeutic benefits for patients than is human embryonic stem cell research (hESCR).